title: The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (IE62) expressed in recombinant herpes simplex virus-1.
abstract: In order to evaluate the conditions for optimal expression and immunogenicity of varicella-zoster virus (VZV) proteins in a herpes simplex virus-1 (HSV-1) vector, we selected the VZV glycoprotein E (gE), encoded by ORF 68 and the VZV product of ORF 62, an immediate-early major tegument protein (IE62). Three HSV/VZV recombinants were generated: (1) VZV gE protein coding sequences along with the promoter region were inserted into the thymidine kinase (TK) gene of HSV-1 strain KOS; (2) VZV gE expressed from the HSV-1 ICP4 promoter was inserted into the glycoprotein C (gC) gene of HSV-1 strain F; and (3) VZV IE62 protein coding sequences under the control of the HSV-1 ICP4 promoter were inserted into the gC gene of HSV-1 strain F. Immunoblot analysis and immunoperoxidase staining of infected cell monolayers demonstrated vector expression of VZV proteins. Following intracranial inoculation in mice, both VZV gE-HSV (TK) and VZV IE62-HSV (gC) induced an IgG response against VZV gE or VZV IE62. When tested in cytotoxicity assays using T-lymphocytes from VZV immune human donors, the range of precursor frequencies for T-lymphocytes that recognized VZV gE or VZV IE62 was similar whether these proteins were expressed by HSV-1 or a vaccinia vector. These experiments demonstrate that HSV-1 is a competent vector for expression of these VZV proteins and support the feasibility of engineering a combined vaccine for these closely related alpha-herpesviruses.
authors.affiliation: Department of Pediatrics, Stanford University School of Medicine, CA 94305-5119, USA.
authors.forename: P W
authors.initials: PW
authors.lastname: Lowry
authors.forename: C M
authors.initials: CM
authors.lastname: Koropchak
authors.forename: C Y
authors.initials: CY
authors.lastname: Choi
authors.forename: E S
authors.initials: ES
authors.lastname: Mocarski
authors.forename: E R
authors.initials: ER
authors.lastname: Kern
authors.forename: P R
authors.initials: PR
authors.lastname: Kinchington
authors.forename: A M
authors.initials: AM
authors.lastname: Arvin
mesh_terms: D000212:Acyclovir / Q000494:pharmacology; D000818:Animals; D000956:Antigens, Viral / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D000998:Antiviral Agents / Q000494:pharmacology; D015139:Blotting, Southern; D002522:Chlorocebus aethiops; D003601:Cytotoxicity Tests, Immunologic; D005822:Genetic Vectors; D006168:Guinea Pigs; D006561:Herpes Simplex / Q000276:immunology / Q000503:physiopathology / Q000821:virology; D018259:Herpesvirus 1, Human / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification / Q000472:pathogenicity; D014645:Herpesvirus 3, Human / Q000235:genetics / Q000276:immunology*; D006801:Humans; D017874:Immediate-Early Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D015151:Immunoblotting; D051379:Mice; D008807:Mice, Inbred BALB C; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D011995:Recombination, Genetic; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D015534:Trans-Activators / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*
chemical_list: D000956:Antigens, Viral; D000998:Antiviral Agents; C074221:IE62 protein, Human herpesvirus 3; D017874:Immediate-Early Proteins; D011993:Recombinant Fusion Proteins; D015534:Trans-Activators; D014759:Viral Envelope Proteins; C056913:glycoprotein E, varicella-zoster virus; D000212:Acyclovir